Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study.
10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C. The regimen was potentiated by lonidamine and supported by autologous bone marrow transplantation. The results of this pilot study were encouraging, with a response rate of 50% and a significantly better survival for responders versus non-responders. No appreciable toxicity of the therapy was observed. This aspect, together with the simplicity of the procedure, calls for further investigations to confirm the good therapeutic index of the treatment.
Third Department of Clinical Medicine, University La Sapienza, Roma, Italy.
F
F
Franchi
P
P
Seminara
G
G
Codacci Pisanelli
V P
VP
Guazzugli Bonaiuti
F
F
Giovagnorio
G
G
Gualdi
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010865:Pilot Projects; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D007191:Indazoles; D016685:Mitomycin; D002330:Carmustine; C016371:lonidamine